Core Insights - Argenx SE will present data for VYVGART and pipeline candidates at the 2026 American Academy of Neurology Annual Meeting, highlighting advancements in treatments for severe autoimmune diseases [1][2][36] Group 1: VYVGART Developments - New Phase 3 results in ocular myasthenia gravis (oMG) will demonstrate VYVGART's potential as a targeted treatment option for patients [2][6] - Positive results from the Phase 3 ADAPT OCULUS study confirm VYVGART's therapeutic potential in adults with oMG, marking a significant advancement in treatment options [5][6] - Data from the ADAPT SERON study supports VYVGART's efficacy across broader patient populations, including generalized myasthenia gravis (gMG) patients without detectable anti-acetylcholine receptor antibodies [6][38] Group 2: Pipeline Candidates - Argenx will share results from the ARGX-119 Phase 1b trial evaluating adimanebart in patients with DOK7 congenital myasthenic syndromes, showing a favorable safety profile and functional improvements [4][38] - Empasiprubart is being evaluated for multiple severe autoimmune indications, including chronic inflammatory demyelinating polyneuropathy (CIDP) and delayed graft function following kidney transplant [28][36] Group 3: CIDP Insights - Results from an ADHERE post hoc analysis will highlight VYVGART Hytrulo's impact in treatment-naïve CIDP patients, supporting its earlier use in treatment paradigms [3][38] - Real-world insights will illustrate physician approaches to transitioning patients from intravenous immunoglobulin (IVIg) to VYVGART Hytrulo, aiming to enhance patient outcomes [3][38]

Core Viewpoint - Artisan Mid Cap Fund's fourth-quarter 2025 investor letter highlights the fund's performance and key stock contributions, particularly focusing on Argenx SE, which has shown significant growth in sales and market capitalization despite some recent setbacks in clinical trials [1][3]. Fund Performance - The Artisan Mid Cap Fund's Investor Class, ARTMX, delivered -0.44%, Advisor Class, APDMX, delivered -0.37%, and Institutional Class, APHMX, delivered -0.35% in Q4 2025, compared to -3.70% for the Russell Midcap® Growth Index [1]. - The performance was bolstered by continued strength in the information technology and healthcare sectors [1]. Key Holdings - Argenx SE (NASDAQ:ARGX) is identified as a leading contributor to the fund's quarterly performance, with a market capitalization of $51.131 billion [2][3]. - The stock closed at $826.25 per share on February 23, 2026, with a one-month return of -0.83% and a 52-week gain of 31.96% [2]. Argenx SE Insights - Argenx SE's VYVGART® sales nearly doubled year-over-year, increasing by 96% to over $4 billion, driven by new patient uptake following the launch of its prefilled syringe formulation [3]. - Despite a recent stock pullback due to the discontinuation of a mid-stage trial for thyroid eye disease, the company remains optimistic about VYVGART®'s potential for additional indications [3]. Hedge Fund Interest - Argenx SE is not among the 30 most popular stocks among hedge funds, with 47 hedge fund portfolios holding the stock at the end of Q4, down from 50 in the previous quarter [4].

Core Insights - Artisan Partners' "Artisan Mid Cap Fund" reported strong performance in Q3 2025, with the Investor Class fund returning 8.80%, Advisor Class fund also at 8.80%, and Institutional Class fund at 8.83%, significantly outperforming the Russell Midcap Growth Index's return of 2.78% [1] - The fund's outperformance was primarily driven by holdings in the health care sector, particularly highlighting Argenx SE (NASDAQ:ARGX) as a top contributor [1][3] Fund Performance - Global equity markets showed strength in Q3 2025, ending the period with double-digit year-to-date gains [1] - The Artisan Mid Cap Fund's returns for the different classes were as follows: Investor Class (ARTMX) 8.80%, Advisor Class (APDMX) 8.80%, and Institutional Class (APHMX) 8.83% [1] Company Spotlight: Argenx SE - Argenx SE (NASDAQ:ARGX) is a commercial-stage biopharma company with a one-month return of 10.70% and a 52-week gain of 50.38%, closing at $812.95 per share with a market capitalization of $149.06 billion on October 14, 2025 [2] - Argenx's VYVGART®, a first-in-class autoimmune therapy, has shown strong growth, supported by a new subcutaneous formulation for self-administration, and is being studied for multiple autoimmune disorders [3] Hedge Fund Interest - Argenx SE (NASDAQ:ARGX) was held by 53 hedge fund portfolios at the end of Q2 2025, a slight decrease from 54 in the previous quarter, indicating a stable interest among hedge funds [4]

Core Insights - Vor Bio has appointed Dr. Navid Z. Khan as Chief Medical Affairs Officer, bringing over two decades of experience in medical affairs, commercial, and R&D functions [1][2] - Dr. Khan has overseen more than 40 development programs and successfully guided seven product launches in neurology and immunology [2] - The company is focused on advancing telitacicept, a novel dual-target fusion protein, through Phase 3 clinical development to address serious autoantibody-driven conditions [5] Company Overview - Vor Bio is a clinical-stage biotechnology company dedicated to transforming the treatment of autoimmune diseases [5] - The company aims to ensure strong scientific exchange, evidence generation, and meaningful engagement with patient and physician communities worldwide [3] Leadership Background - Dr. Khan previously held senior leadership positions at argenx, Akouos Inc., and Sarepta Therapeutics, where he played a pivotal role in launching therapies for Duchenne muscular dystrophy [2][3] - He earned his Ph.D. in Biomedical Engineering and Biotechnology and holds a B.S. in Biochemistry and Molecular Biology [4]

Core Insights - The European Commission has approved VYVGART® (efgartigimod alfa) for subcutaneous injection as a monotherapy for adult patients with chronic inflammatory demyelinating polyneuropathy (CIDP) after prior treatment with corticosteroids or immunoglobulins [1][4] - VYVGART is the first targeted IgG Fc-antibody fragment for CIDP and introduces a novel mechanism of action for CIDP treatment in over 30 years [2] - The approval is based on positive results from the ADHERE clinical trial, the largest study of CIDP patients to date, and is valid across all 27 EU Member States, as well as Iceland, Norway, and Liechtenstein [4] Company Overview - Halozyme Therapeutics, Inc. specializes in biopharmaceutical solutions aimed at improving patient experiences and outcomes, particularly through its ENHANZE® drug delivery technology [5] - The company has impacted over one million patients through its commercialized products and has licensed its ENHANZE® technology to major pharmaceutical companies including Roche, Takeda, and Pfizer [5] - Halozyme also develops drug-device combination products using advanced auto-injector technologies to enhance patient comfort and adherence [6] Strategic Partnerships - The approval of VYVGART represents a significant milestone in Halozyme's partnership with argenx, expanding access to CIDP treatment in Europe [3] - The company continues to collaborate with various pharmaceutical and biotechnology firms to leverage its ENHANZE® technology for improved drug delivery [5][6]